Glenmark Pharmaceuticals has received final USFDA approval for its generic version of anti-inflammatory drug Indomethacin tablets. The drug is the generic equivalent of Indocin SR Extended- Release capsules, 75 mg of Iroko Pharmaceuticals LLC. The drug has a market potential of USD 6.3 million according to industry estimates. Glenmark’s current portfolio consists of 118 products authorised for distribution in the US and 67 ANDA’s pending approval with the USFDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply